naltrexone has been researched along with Angiogenesis, Pathologic in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kast, RE | 1 |
| Donahue, RN; McLaughlin, PJ; Zagon, IS | 2 |
1 review(s) available for naltrexone and Angiogenesis, Pathologic
| Article | Year |
|---|---|
Use of FDA approved methamphetamine to allow adjunctive use of methylnaltrexone to mediate core anti-growth factor signaling effects in glioblastoma.
Topics: Brain Neoplasms; Central Nervous System Stimulants; Drug Approval; Drug Synergism; Glioblastoma; Humans; Methamphetamine; Naltrexone; Narcotic Antagonists; Neovascularization, Pathologic; Quaternary Ammonium Compounds; United States; United States Food and Drug Administration; Vascular Endothelial Growth Factor A | 2009 |
2 other study(ies) available for naltrexone and Angiogenesis, Pathologic
| Article | Year |
|---|---|
The opioid growth factor (OGF) and low dose naltrexone (LDN) suppress human ovarian cancer progression in mice.
Topics: Animals; Apoptosis; Cell Line, Tumor; Disease Progression; DNA; Enkephalin, Methionine; Female; Humans; Mice; Mice, Nude; Naltrexone; Narcotic Antagonists; Neovascularization, Pathologic; Ovarian Neoplasms; Receptors, Opioid; Xenograft Model Antitumor Assays | 2011 |
Low-dose naltrexone suppresses ovarian cancer and exhibits enhanced inhibition in combination with cisplatin.
Topics: Animals; Antineoplastic Agents; Cell Line; Cell Proliferation; Cisplatin; Disease Models, Animal; Drug Therapy, Combination; Female; Humans; Mice; Mice, Nude; Naltrexone; Neovascularization, Pathologic; Ovarian Neoplasms; Paclitaxel; Treatment Outcome | 2011 |